$2,367.51 general Payment -- Gilead Sciences to Dr. Lisa Garcia
Gilead Sciences payment to Infectious Disease specialist for services related to Opdivo
This page provides a detailed analysis of a $2,367.51 general payment from Gilead Sciences to Dr. Lisa Garcia. Data is from the CMS Open Payments (Sunshine Act) database.
Payment Details
| Field | Value |
|---|---|
| Amount | $2,367.51 |
| Payment Type | general |
| Payment Nature | Compensation for services other than consulting |
| Pharmaceutical Company | Gilead Sciences |
| Physician | Dr. Lisa Garcia |
| NPI Number | 1043907541 |
| Physician Specialty | Infectious Disease |
| Location | City, LA |
| Date of Payment | 2025-08-05 |
| Related Drug/Device | Opdivo |
| Conflict Assessment | Moderate -- Worth Noting |
AI-Powered Analysis of This Payment
The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.
Gilead Sciences made a $2.4K general payment to Lisa Garcia, a Infectious Disease specialist in City, LA. The payment was associated with Opdivo. The payment of $2,367.51 to Dr. Lisa Garcia from Gilead Sciences is for services other than consulting. The payment is associated with the drug Opdivo, a treatment often used in oncology. Dr. Garcia's specialty is Infectious Disease, which may or may not directly align with the primary use of Opdivo.
Patient Guidance: What This Payment Means for You
If you are a patient receiving treatment, discuss with your doctor how any payments received by them might influence your care options. Always discuss your treatment options with your healthcare provider and ask about alternatives.
Payment Context: Is This Amount Normal?
Payments to Infectious Disease specialists are generally lower than those for oncologists, but this payment's context requires further investigation due to the oncology drug association.
Regulatory Context: Sunshine Act Requirements
Payments to physicians must be reported under the Sunshine Act, and physicians should ensure such payments are for legitimate services and do not influence prescribing habits.
Related Topics
This payment is related to the following healthcare transparency topics:
- pharmaceutical-payments
- physician-compensation
- drug-association
- infectious-disease
- oncology-drug
- open-payments-data
Understanding general Payments
general payments are one of several categories of financial transfers from pharmaceutical and medical device companies to physicians that must be reported under the Sunshine Act. Understanding the type and context of a payment is important for evaluating its significance. Not all payments are equal -- a research grant has very different implications than a promotional speaking fee.
Frequently Asked Questions About This Payment
What was this $2.4K payment for?
This was a general payment of $2.4K from Gilead Sciences to Lisa Garcia, categorized as "Compensation for services other than consulting". It was associated with Opdivo. The payment was reported under the Sunshine Act (CMS Open Payments).
Does Lisa Garcia accept pharmaceutical money?
Yes, Lisa Garcia received this $2.4K payment from Gilead Sciences. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Lisa Garcia's full payment history on the CMS Open Payments database or on this site.
Is it legal for doctors to accept pharma payments?
Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.
Should I be concerned about this general payment?
A general payment of $2.4K should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.
How do I talk to my doctor about pharma relationships?
You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.
What types of pharma payments are most concerning?
Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.
Does pharma money affect what my doctor prescribes?
Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.
How does this compare to other doctors in Infectious Disease?
To compare this payment against Infectious Disease averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Infectious Disease physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.
What does this payment reveal about Lisa Garcia's relationship with Gilead Sciences?
The payment nature specifies 'Compensation for services other than consulting,' indicating a direct service provided by the physician. This $2.4K general payment is part of the transparency data reported under the Sunshine Act.
Is this payment amount typical for Infectious Disease?
The drug associated with the payment, Opdivo, is primarily an immunotherapy drug used in cancer treatment.
What should patients do after learning about this payment?
If you are a patient receiving treatment, discuss with your doctor how any payments received by them might influence your care options.
What else should I know about this general payment?
Dr. Garcia's specialty is Infectious Disease, raising a question about the direct relevance of Opdivo to her practice.
Related Reports
Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.